Mycoplasma genitalium infection

CMAJ. 2019 Jan 28;191(4):E103. doi: 10.1503/cmaj.180881.

Authors

Ameeta E Singh¹, Annie-Claude Labbé², Ulrick Auguste²

Affiliations

¹ University of Alberta (Singh), Edmonton, Alta.; Université de Montréal (Labbé), Montréal, Que.; Public Health Agency of Canada (Auguste), Ottawa, Ont. ameeta@ualberta.ca.
² University of Alberta (Singh), Edmonton, Alta.; Université de Montréal (Labbé), Montréal, Que.; Public Health Agency of Canada (Auguste), Ottawa, Ont.

No abstract available

MeSH terms

Anti-Bacterial Agents / therapeutic use
Azithromycin / therapeutic use
Canada / epidemiology
Drug Resistance, Bacterial / drug effects*
Female
Fluoroquinolones / therapeutic use
Health Surveys
Humans
Male
Moxifloxacin / therapeutic use
Mycoplasma Infections / diagnosis*
Mycoplasma Infections / drug therapy
Mycoplasma Infections / epidemiology
Mycoplasma genitalium / pathogenicity*
Practice Guidelines as Topic
Prevalence
Sexually Transmitted Diseases, Bacterial / drug therapy
Sexually Transmitted Diseases, Bacterial / epidemiology
Sexually Transmitted Diseases, Bacterial / microbiology*

Substances

Anti-Bacterial Agents
Fluoroquinolones
Azithromycin
Moxifloxacin